Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0031117 (peripheral neuropathy)
 10,577 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty-six adults with advanced non-Hodgkin's lymphoma (73% in clinical stage IV) were treated with a combination of cyclophosphamide, hydroxyldaunorubicin, vincristine, prednisolone and bleomycin (modified CHOP-Bleo), from May 1978 to July 1987. Complete remission (CR) was obtained in 12 of 26 patients (46%). The median survival time was 19.5 months (2-77 + months), Median duration of CR was 30.5 months (2-76 + months). The survival of patients with diffuse lymphoma large cell type (DL) was better than those with other diffuse lymphomas. The 50% of patients with DL are projected to be free of disease. The survival of patients with clinical stage III was significantly better than those with clinical stage IV. Major complications during chemotherapy with modified CHOP-Bleo were myelosuppression, constipation and peripheral neuropathy. These toxicities were generally mild and well tolerated.
 ...
PMID:[Combination chemotherapy (modified CHOP-Bleo) in non-Hodgkin's lymphoma]. 168 99

COP-BLAM III therapy was given to 18 patients with non-Hodgkin's lymphoma, and the therapeutic effects as well as adverse effects of the treatment were examined. Of the 18 patients 16 had a complete remission (CR) and 2 showed an partial remission (PR) with a total response rate of 100%. In terms of the stage of disease, CR was achieved in all patients in stage III and in 11 of 13 patients in stage IV. Patients with neutrophil counts less than 1,000/microliters were given rhG-CSF (1.5 micrograms/kg/day, sc), which significantly shortened the duration of neutropenia and decreased the number of days with episodes of fever when compared with those not given rhG-CSF, consequently facilitating the treatment without prolonging the dosing intervals. No serious infection was observed. Adverse effects included neutropenia of less than 1,000/microliters in 6 of the 18 patients (33.3%), thrombocytopenia less than 5 x 10(4)/microliters in 3 (16.7%), nausea and vomiting in 8 (44.4%), peripheral neuropathy in 4 (22.2%) and stomatitis in 4 (22.2%). There were no fatalities caused by the treatment. The above findings indicate that COP-BLAM III therapy is capable inducing high frequency of complete remissions in non-Hodgkin's lymphoma and that its combination with G-CSF can improve the results of the therapy and relieve adverse reactions.
 ...
PMID:[The COP-BLAM III therapy of non-Hodgkin's lymphoma]. 172 37

A 35-year-old man with refractory low grade diffuse centroblastic centrocytic non-Hodgkin's lymphoma was treated accidentally with an overdose of multiple chemotherapeutic agents. He was given adriamycin 50 mg/m2 and cyclophosphamide 350 mg/m2 for 6 days followed by 4 days of vincristine 1 mg/m2 and bleomycin 10 mg/m2. He was transferred when he developed pancytopenia, fever, severe mucositis, ileus and peripheral neuropathy. He was treated with broad spectrum antibiotics, red cell and single donor platelet transfusions and strict parenteral nutrition. In addition, he was given a continuous infusion of 400 micrograms daily human recombinant granulocyte macrophage-colony stimulating factor (rh GM-CSF) for 17 days. Intractable severe bleeding from his oral mucositis necessitated treatment with a continuous infusion of 8-ornithine-vasopressin for 8 days. He recovered and could be discharged home after 36 days of hospitalization with normal blood counts and without severe sequelae.
 ...
PMID:Accidental overdose of multiple chemotherapeutic agents. 248 48

A high incidence of severe peripheral neuropathy occurred during the pilot study of a new regimen for the treatment of non-Hodgkin's lymphoma. The clinically observed incidence and severity of vincristine-induced peripheral neuropathy was considerably enhanced by the sequential use of vincristine and teniposide in this combination chemotherapy.
 ...
PMID:Vincristine neurotoxicity enhanced in combination chemotherapy including both teniposide and vincristine. 300 12

In an effort to improve the treatment of patients with refractory or recurrent lymphoma, we developed a protocol using cis-platinum combined with two other agents of known efficacy in these disorders but with differing side effects: VP-16 and MGBG. Twenty-six eligible patients were treated with this regimen. There were 15 men and 11 women with a median age of 54 years (22-73), and performance status of 1 (0-3). Their diagnoses were Hodgkin's disease 5 and non-Hodgkin's lymphoma [NHL] 21 which included 11 with diffuse histocytic lymphoma [DHL]. The median number of chemotherapy regimens was 2 (1-5); 12 also received radiotherapy. Twenty patients are evaluable for response: 15 NHL and 5 Hodgkin's disease. Three patients, all of whom had DHL entered complete remission (20%) with a median time to treatment failure of 7 1/2 months. Six NHL (40%) and one Hodgkin's disease (20%) patients entered a partial remission. There were three early deaths: one due to progressive disease, one to acute respiratory failure, and one with disease status undocumented. Toxicity included leukopenia, thrombocytopenia, anorexia, nausea, vomiting, stomatitis, alopecia, renal failure, profound peripheral neuropathy, and hypersensitivity vasculitis. Treatment was stopped because of the latter two. These agents are non-crossresistant with doxorubicin-containing regimens. The drugs are possibly synergistic and modestly active with moderate to severe toxicity.
 ...
PMID:Cisplatin, VP-16-213 and MGBG (methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study. 319 89

Clinical studies of combination therapy with chemotherapeutic agents and interferon (IFN) were performed. Seventeen patients with non-Hodgkin's lymphoma (NHL) and 2 patients with Hodgkin's disease (HD) were treated by combination chemotherapy (COPP or CHOP), and then received 300 X 10(4) U of alpha-IFN daily for 14 days. Complete remission was seen in 11 of 15 evaluable patients with NHL and both of 2 patients with HD. Myelosuppression such as leukopenia and thrombocytopenia was observed in half of the patients. Other side effects were fever, liver dysfunction, alopecia, and peripheral neuropathy. However, all these side effects were mild and well tolerated even in elderly patients.
 ...
PMID:[A preliminary study of chemo-interferon therapy in malignant lymphoma]. 380 Apr 2

Nineteen patients with advanced non-Hodgkin's lymphoma (NHL) (stages III and IV) receiving no prior chemotherapy were treated with a combination of cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) at Saitama Cancer Center between January 1977 and February 1979. The overall complete response rate was 11 of 19 or 50%, with 8 of 13 or 62% of patients with diffuse mixed and large cell type of NHL. The median survival for all patients was 41 months. The survival curve of complete responders became flat at 41 months and was well sustained with an actuarial survival of 72%. The survival of patients with stage III was significantly better than those with stage IV (p less than 0.05), while the survival of patients with Waldeyer's ring primary was not significantly superior to patients with nodal primary. A major complication during CHOP-Bleo regimen was myelosuppression, and peripheral neuropathy and reversible interstitial pneumonitis (2 cases) were also observed.
 ...
PMID:[Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma]. 619 77

Fifty-two patients with localized (stage I-II) non-Hodgkin's lymphoma were treated with a combination of vincristine, cyclophosphamide and prednisolone (VCP) as an adjuvant therapy between 1975 and 181. Forty-two patients had extended-field radiotherapy, and ten patients had only surgical excision (6 gastrointestinal tract, 2 breast, one each of skin and axillary lymph node). Clinical stages of these patients were divided into stage I (21 patients) and stage II (31 patients). With a median follow-up time of relapse-free survival (RFS) were calculated by Kaplan and Meier method. At two years after the initiation of chemotherapy, survival and RFS were 95% and 83% for stage I, and 76% and 74% for stage II, respectively. These ratios remained stable for 7 years. Survival and RFS of diffuse histiocytic lymphoma (34 patients) were 90% and 83% at 7 years, while these of diffuse poorly differentiated lymphocytic lymphoma (18 patients) were 75% and 69% at 4 years. Of 52 patients, 10 had relapsed (Stage I: 3 patients and stage II: 7 patients) within the first 2 years. Side effect was minimal with moderate peripheral neuropathy due to vincristine. The result suggests that adjuvant chemotherapy is necessary to improve prognosis of patients with localized non-Hodgkin's lymphoma.
 ...
PMID:[Adjuvant chemotherapy for localized non-Hodgkin's lymphoma with CVP therapy]. 668 53

Thirty-one patients with advanced non-Hodgkin's lymphoma were treated with a combination chemotherapy (VCP therapy), including vincristine (1 mg, weekly), cyclophosphamide (350mg/m2, IV every two weeks) and prednisolone (60mg/day, 1-5 days PO, every two weeks), as an out-patient basis, from May 1974 to October 1977. Characteristics of 31 patients were as follows: median age (56 years), histological types by Rappaport's classification (nodular 2, diffuse 29, NPDL 2, DWDL 5, DPDL 10 and DH 14), clinical stages (II 4, III 9, IV 18), systemic symptoms (A 13, B 18), extranodal presentation (28) and prior treatment (17). Response was evaluated in 28 patients with measurable disease. Complete response (CR) was obtained in 15 patients (53%) and partial response (PR) in 5 (18%). Median time to CR was 20 (6-79) days, and response duration of CR was 14 (1.5-78+) months. Survival time was 19 (1-76) months for all patients, 26 (3-78) months for patients with CR, 9 (3-51) months for patients with PR, and 4 (1-41) months for non-responders. Survival of complete responders was significantly better than that of patients with non-CR. Survival rates of complete responders were 80% (1 year), and 47% (3 year). Toxicities of VCP therapy were relatively mild and reversible with peripheral neuropathy, hair loss and leukopenia. The results indicate that it is necessary to perform more intensive combination chemotherapy adding potent agents for a higher CR rate and a longer CR duration.
 ...
PMID:[Chemotherapy for advanced non-Hodgkin's lymphoma with CVP therapy]. 668 54

Nineteen patients with malignant lymphomas were treated with 52 courses of high dose methotrexate with leucovorin rescue (HDMTX-LCV): 17 non-Hodgkin's lymphoma (11 nodal primary, and 6 Waldeyer's ring), 1 Hodgkin's disease, and 1 Burkitt's lymphoma; 10 No prior chemotherapy, 9 prior chemotherapy; Median age 50 years (18-67); Sex M 13:F 6. MTX was given according to Frei III et al's regimen(1975). In brief, alkalinization of the urine was achieved by administration of NaHCO3 both by oral and by intravenous route. Hydration with at least 3 liters of fluid per day was maintained throughout each course. MTX was administered as a six-hour infusion at an initial dose of 0.5-1.0 g/m2 with gradual escalation to 3-5 g/m2. Thirty minutes before the infusion of MTX, 1.4 mg/m2 of vincristine (VCR) (maximum dose 2 mg) was given intravenously in each course. MTX levels were not monitored. The overall response rate was 63% with 7 partial responses and 5 complete responses. Five of 10 previously untreated patients and 7 of 9 patients with prior chemotherapy achieved an objective response. Our excellent result may be contributed in part by VCR. Although, in general, during this study HDMTX-LCV was well-tolerated, a 67 year-old male had severe and unpredictable toxicity which resulted in shock condition, leukopenia and thrombocytopenia. Accordingly, we feel that HDMTX-LCV is dangerous without monitoring plasma MTX level. In other side effects, peripheral neuropathy and constipation possibly due to VCR occurred especially in elderly patients.
 ...
PMID:[High dose methotrexate with leucovorin rescue in the treatment of malignant lymphoma]. 698 94


1 2 3 Next >>